|
|||||
|
|
Nine-week trastuzumab treatment versus 52-week trastuzumab treatment for HER2-positive early-stage breast cancer |
|
| Authors: | Onder Tonyali Ugur Coskun Nur Sener Mevlude Inanc Tulay Akman Berna Oksuzoglu Nuriye Yildirim Ozdemir Dogan Yazilitas Mustafa Benekli Aytug Uner Deniz Yamac Umut Demirci Ramazan Yildiz Halit Karaca Olcun Umit Unal Oznur Bal Mahmut Gumus Suleyman Buyukberber |
| Affiliation: | 1. Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Gazi University, 06500, Besevler, Cankaya, Ankara, Turkey 2. Department of Medical Oncology, Dr. Lutfi Kirdar Kartal Education and Research Hospital, Istanbul, Turkey 3. Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Erciyes University, Kayseri, Turkey 4. Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey 5. Department of Medical Oncology, Ankara Oncology Training and Research Hospital, Ankara, Turkey 6. Department of Medical Oncology, Ankara Numune Education and Research Hospital, Ankara, Turkey 7. Department of Medical Oncology, Konya Numune Education and Reseach Hospital, Konya, Turkey 8. Department of Medical Oncology, Ankara Ataturk Education and Research Hospital, Ankara, Turkey |
| Abstract: | PurposesTrastuzumab is known to be effective for early and advanced stages of breast cancer but optimal duration for early-stage breast cancer (EBC) is not well known. We evaluated the efficacy and toxicity of 9- and 52-week trastuzumab therapy for EBC retrospectively.MethodsIn this multicenter study, the medical records of all patients with EBC were analyzed in 8 centers retrospectively. Totally consecutive, 479 female patients who received trastuzumab in the adjuvant treatment were evaluated for disease-free survival (DFS), overall survival (OS), efficacy, and toxicity.ResultsThere were 181 (37.8?%) and 298 (62.2?%) patients in the 9- and 52-week trastuzumab groups, respectively. Median follow-up was 30.6?months (5.7–68.9) in the 9-week trastuzumab group and 29.3?months (5.9–59.6) in the 52-week trastuzumab group. Thirty-six month DFS was 90 and 85?% (P?=?0.132) in the 9- and 52-week trastuzumab treatment groups, respectively, and 36-month OS was 96 and 97?% in the 9- and 52-week trastuzumab groups, respectively (P?=?0.779). Symptomatic cardiotoxicity was observed in 1 (0.6?%) patient in the 9-week trastuzumab group and in 4 (1.3?%) patients in the 52-week trastuzumab group.ConclusionsIn this study, similar outcomes were found in the 9- and 52-week trastuzumab treatment groups. |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |